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Gla-300 for ≥8 weeks prior to inclusion, and intended to 
continue its use during Ramadan were enrolled in 11 coun-
tries. During Ramadan, Gla-300 treatment was adjusted 
as per routine practice by the treating physician. Overall, 
the majority of people (402 [85%]) fasted for the entire 
Ramadan period and 10.8% fasted for ≥25 days but with at 
least one missed day. Mean (SD) age was 54.4 (11.0) years, 
51.7% were male, BMI was 29.7 (5.3) kg/m2, and duration 
of diabetes was 10.7 (7.0) years. Risks of diabetes-related 
complications associated with fasting were assessed by 
physicians according to IDF-DAR fasting risk category; 
risk was low/moderate in 82.8%, high in 14.3%, and very 
high in 2.9% of people. The proportion of people with ≥1 
severe and/or documented symptomatic (SMPG ≤70  mg/
dL) hypoglycemia event was low (2.2% [event rate: 0.021 
per participant-month (PPM)] in pre-Ramadan, 2.6% 
[0.039 PPM] in Ramadan and 0.2% in post-Ramadan 
[0.003 PPM]). Overall, 0.8% (0.005 PPM) of participants 
experienced severe and/or documented symptomatic hy-
poglycemia at SMPG <54  mg/dL, and only during pre-
Ramadan. No participants had severe hypoglycemia during 
Ramadan or post-Ramadan; 1 participant had severe hy-
poglycemia pre-Ramadan. Most of those who experienced 
symptomatic hypoglycemia during Ramadan did so during 
fasting hours (11/13 people). Reductions were shown pre- 
to post-Ramadan for mean (SD) HbA1c (8.10 % [1.29] pre-
Ramadan to 7.64 % [1.05] post-Ramadan; change of −0.44 
% [0.97]), FPG (144.3 [45.8] mg/dL pre-Ramadan to 128.5 
[37.8] mg/dL post-Ramadan; change of −13.5 [44.1] mg/
dL), and fasting SMPG (130.7 [32.9] mg/dL pre-Ramadan 
to 126.8 [28.5] mg/dL post-Ramadan; change of −3.3 [26.6] 
mg/dL). Mean Gla-300 dose was reduced slightly between 
pre-Ramadan and Ramadan (25.6 [11.9] U/0.32 [0.14] U/kg 
pre-Ramadan to 24.4 [11.5] U/0.30 [0.13] U/kg in Ramadan) 
and returned to 26.0 (12.2) U/0.32 (0.14) U/kg in the post-
Ramadan period. AE incidence was low (5.5%); 3 (0.6%) 
participants had an AE of hyperglycemia, 2 (0.4%) during 
Ramadan. In this study, performed in a real-world setting, 
incidence of hypoglycemia was low in people with T2DM 
treated with Gla-300 who fasted for Ramadan, with no in-
cidence of severe hypoglycemia during the Ramadan pe-
riod; HbA1c, FPG and fasting SMPG reductions were also 
observed. Supported By: Sanofi
Thyroid
NO LONGER A PAIN IN THE NECK — 
RECENT INSIGHT INTO THYROID GROWTH, 
DEVELOPMENT, AND PATHOLOGY
Drug Repurposing Identifies Inhibitors of the 
Proteostasis Network to Augment Radioiodine 
Uptake in Combinatorial Approaches Targeting 
Thyroid Cancer
Martin L. Read, PhD1, Katie Brookes, BSc1, Alice Fletcher, PhD1, 
Caitlin E.M Thornton, BSc1, Mohammed Alshahrani, BSc1, 
Rashida Khan, BSc1, Hannah R. Nieto, MD1, Holly V. Adcock, 
PhD2, Jamie R.M Webster, BSc3, Liam Cox, PhD2, Luke J. 
Alderwick, PhD4, Kristien Boelaert, MD5, Vicki E. Smith, PhD1, 
Christopher J. McCabe, PhD1.
1Institute of Metabolism and Systems Research, University 
of Birmingham, Birmingham, United Kingdom, 2School of 
Chemistry, University of Birmingham, Birmingham, United 
Kingdom, 3Protein Expression Facility, College of Medical and 
Dental Sciences, University of Birmingham, Birmingham, United 
Kingdom, 4Institute of Microbiology and Infection, School of 
Biosciences, University of Birmingham, Birmingham, United 
Kingdom, 5Institute of Applied Health Research, University of 
Birmingham, Birmingham, United Kingdom.
OR28-03
New combinatorial drug strategies are urgently needed 
to improve radioiodine (RAI) uptake and efficiently ablate 
thyroid cancer cells, thereby reducing the risk of recurrent 
disease. Drug repurposing offers the promise of identifying 
already approved compounds capable of inducing sodium 
iodide symporter (NIS) function to enhance iodide uptake. 
However, a lack of thyroid cell-based assays amenable 
to high-throughput screening has limited progress. We 
utilised the mutated yellow fluorescent protein (YFP) as a 
surrogate biosensor of intracellular iodide and screened the 
Prestwick Chemical Library (1200 drugs; 95% approved) 
for quenching of YFP fluorescence. This allowed us to iden-
tify putative candidate drugs which increased iodide up-
take >2 SD above mean. Categorisation of these revealed 
a high proportion of drugs that modulate the proteostasis 
network (19/48; ~40%), including key processes in protein 
homeostasis such as endoplasmic reticulum-associated 
protein degradation (ERAD) and autophagy. Secondary 
screening validated the activity of proteostasis modulators 
in enhancing iodide uptake after ranking 73 leading 
compounds based on their pharmacologic (AUC, EMAX and 
EC50) and specificity of response (NIS+ve vs NIS-ve YFP-
thyroid cells) at ten different drug doses (0.1 to 50  μM). 
Of importance, several repurposed drugs (e.g. ebastine, 
Prestwick N, Prestwick C and clotrimazole) in combination 
with the HDAC inhibitor vorinostat induced a robust en-
hancement in RAI uptake in thyroid cancer cells (TPC-1 
and 8505C NIS+ve cells, up to 11-fold vs DMSO, P<0.001), 
which was significantly greater than using vorinostat alone 
(up to 3-fold, P<0.01). For clotrimazole, we designed 7 new 
chemical derivatives, 3 of which showed enhanced aqueous 
solubility and retained the ability to significantly enhance 
RAI uptake. TaqMan RT-PCR revealed that, in contrast to 
vorinostat, our repurposed drugs failed to alter NIS mRNA 
expression, highlighting post-transcriptional mechanisms. 
Critically, 11 repurposed drugs induced significant gains in 
RAI uptake in human primary thyroid cells (up to 4.1-fold; 
P<0.05), the most physiological setting for NIS function. 
In conclusion, we performed high-throughput screening 
and identified proteostasis modulators, as well as other 
repurposed drugs, that markedly enhance radioiodine up-
take. Further clinical investigation of these drugs might 
offer new combinatorial approaches, especially with ex-
isting therapies, to improve the treatment of thyroid cancer.
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